Full Press Release Details
Alterity CEO Dr David Stamler presents
the HC Wainwright Global Life Science
MELBOURNE, AUSTRALIA AND SAN FRANCISCO,
USA - 10th March 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the
Company") CEO Dr David Stamler is presenting to US investors this week as part of the HC Wainwright Global Life Science Conference.
The conference held virtually, attracts
specialist life science and healthcare investors and features leading companies from around the world.
Dr Stamler's presentation is appended and includes:
Dr Stamler said: "Alterity has made significant progress
over this last 6-12 months and we are pleased with the growing interest from investors, scientists and clinicians."
Authorization & Additional information
This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.
Greig King, WE Communications
About Alterity Therapeutics Limited
Alterity's lead candidate, ATH434
(formerly PBT434), is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins
implicated in neurodegeneration. ATH434 has been shown to reduce abnormal accumulation of -synuclein and tau proteins in
animal models of disease by redistributing labile iron in the brain. In this way, it has potential to treat Parkinson's disease
and atypical forms of Parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).
ATH434 has been granted Orphan designation for the treatment
of MSA by the US FDA and the European Commission.
For further information please visit the Company's website
About Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare
and rapidly progressive neurological disorder affecting adults. It has no known cause. In addition to presenting with motor symptoms
like those in Parkinson's disease, individuals with MSA may also experience loss of ability to coordinate voluntary movements
and impaired regulation of involuntary body functions such as blood pressure, bowel and bladder control. Most of these symptoms
are not addressed by available drugs for patients with Parkinson's disease. As the condition progresses, daily activities
become increasingly difficult and complications such as increased difficulty swallowing, vocal cord paralysis, progressive immobility,
and poor balance become more prominent. Symptoms tend to appear after age 50 and rapidly advance, leading to profound disability.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act
of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends,"
"hopes," "anticipates," "believes," "could," "may," "evidences"
and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual
results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk
Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports
on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program,
including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development
program, including, but not limited to, ATH434 (formerly PBT434), and any other statements that are not historical facts. Such
statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties
or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components,
including, but not limited to, ATH434, uncertainties relating to the impact of the novel coronavirus (COVID-19) pandemic on the
company's business, operations and employees, the ability of the Company to procure additional future sources of financing,
unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited
to, ATH434, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's
intellectual property or trade secrets, including, but not limited to, the intellectual property relating to ATH434.
Any forward-looking statement made by
us in this press release is based only on information currently available to us and speaks only as of the date on which it is made.
We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or otherwise.